Core Viewpoint - Sanofi's subsidiary, Sirnaomics, Inc., has completed the Phase I trial of the investigational drug STP707 and has formally submitted the clinical research report to the FDA [1] Group 1: Clinical Trial Details - The Phase I trial included adults with advanced, metastatic, or unresectable solid tumors that had progressed or were unresponsive to standard treatments [1] - STP707 demonstrated clinical activity in these patients, with some achieving disease stabilization and delaying disease progression in a population with limited treatment options [1] - Patients received different doses of STP707 via intravenous administration, with most side effects being manageable [1] Group 2: Regulatory and Development Plans - The completion of the Phase I trial and submission of the clinical research report is considered a key milestone for STP707 [1] - Following the submission, Sirnaomics, Inc. is preparing to initiate discussions with the FDA to determine the strategy for Phase II development [1]
圣诺医药-B(02257)完成试验药物STP707的I期试验并已向FDA正式提交临床研究报告